Russia’s competition authority approved of Sistema’s buyout of Veropharm on Monday, and, as a result, shares surged in the Moscow stock exchange for two of nation’s pharmaceutical companies, Veropharm and 36.6. Shares in 36.6 rose 6.7 percent, while shares for Veroharm – Russia’s third largest drug maker – rose 9.7 percent. 36.6 had previously announced it was ready to sell its share in Veropharm, which amounted to 51.8 percent of the company, to pay off debts. Russia’s Federal Anti-Monopoly Service has approved of the merger as long as certain conditions are met, though there is no word yet on what those conditions are.
Full Content: RiaNovosti
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI